Hematopoietic stem cells

Pluripotent cells.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Hematopoietic stem cells are pluripotent progenitor cells with self-renewal capability. They can differentiate into any haematopoietic system cell (Ng and Alexander, 2017). Transplantation of HSCs is used for the treatment of several haematological, malignant and immune disorders (Duarte et al., 2019).

Hematopoietic stem cells on Wikipedia


Haematopoietic stem cells; HSCs


Supporting references

Link Tested on Impact factor Notes Publication date
Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response
Stem cells Cell-based therapy Case report Mixed substance
T and B lymphopenia patients 5.48

2 patients who received HSC transplantation due to their medical conditions (not related to COVID-19) were infected with SARS-CoV-2. Despite their immune deficiencies, the infection was mild. One of the patients died 52 days post transplantation with no signs of viral infection. Acute grade 4 graft versus host disease developed in this patient, however. Sample size: 2. 


AI-suggested references